The binding of APO2L/TRAIL to liposomes resulted in the production of artificial lipid vesicles, which demonstrated therapeutic potential in the treatment of rheumatoid arthritis and hematological tumor.234–236 Furthermore, Zheng et al.237 fabricated triptolide-loaded membrane protein-chimeric liposomes, and demonstrated that they exhibited good tumor targeting while mitigating the toxicity of triptolide. The gene discussed is TNFSF10; the disease is rheumatoid arthritis.